Inicio › Leucemia bifenotípica aguda › Misuri
Ensayos clínicos de Leucemia bifenotípica aguda en Misuri
5 estudios sobre Leucemia bifenotípica aguda buscan participantes en Misuri.
Ciudades en Misuri
Texto oficial del estudio (inglés)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Mercy Hospitals and Clinics, Kansas City
- Washington University School of Medicine, St Louis
- Mercy Hospital Saint Louis, St Louis
ReclutandoFase 2
365 Days · Todos los sexos · Actualizado el 25 sept 2026 · NCT06317662A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Washington University in St. Louis School of Medicine, St Louis
ReclutandoFase 1/2
30 Days · Todos los sexos · Actualizado el 16 sept 2026 · NCT04065399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Missouri Children's Hospital, Columbia
- Children's Mercy Hospitals and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- y 2 más
ReclutandoFase 3
365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Missouri Children's Hospital, Columbia
- Children's Mercy Hospitals and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- y 2 más
ReclutandoFase 1/2
Hasta los 22 · Todos los sexos · Actualizado el 25 ago 2026 · NCT04726241Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Mercy Hospital of Kansas City, Kansas City
ReclutandoFase 1
Edades de 1 a 30 · Todos los sexos · Actualizado el 3 ago 2026 · NCT06177067De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.